Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Clene Inc. CLNN

MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Posted on September 28, 2023 by MissionIR

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

Posted on September 28, 2023 by MissionIR

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s disease, and multiple sclerosis (“MS”). Its lead drug candidate is CNM-Au8(R), an … Continue reading →

Posted in Clene Inc. CLNN | Leave a comment